Akums Drugs & Pharma logo

Akums Drugs & Pharma

AKUMS NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹11,782 Cr
Volatility
Moderate
P/E Ratio
41.9
EBITDA
₹651 Cr
Return on Equity
7.7%
Debt to Equity
0.05
Book Value
₹210.57
EPS
₹0
52W High
₹796.55
52W Low
₹409.3

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

3
  • Stock is trading at 3.69 times its book value
  • The company has delivered a poor sales growth of 9.87% over past five years.
  • Company has a low return on equity of 9.89% over last 3 years.

Growth Rate

Revenue Growth
7.61% higher than 3Y
Net Income Growth
-25.42% lower than 3Y
Cash Flow Change
154% higher than 3Y
ROE
-31.37% lower than 3Y
ROCE
-7.29%
EBITDA Margin (Avg.)
17.03% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk medium

Akums Drugs & Pharmaceuticals trades at a market cap of ₹9,883 Cr with a PE of 38.4x and is nearly debt-free. However, recent TTM profit growth has turned negative at -14% and ROE remains modest at 8-10%, presenting a mixed picture for a healthcare CDMO player at this valuation.

Bull Case 7
  • Company is almost debt-free, providing significant financial flexibility and low interest burden in a capital-intensive pharma sector
  • Compounded profit growth of 29% over 3 years demonstrates strong earnings trajectory over the medium term
  • Long-term compounded sales growth of 10% over both 5-year and 10-year periods shows consistent revenue expansion
  • Compounded profit growth of 16% over both 5-year and 10-year horizons indicates sustainable long-term earnings compounding
  • Dividend yield of 0.48% provides some income return, uncommon among growth-stage pharma companies
  • Stock has delivered 8% CAGR over 1 year, indicating positive price momentum despite broader market volatility
  • CDMO business model in India's growing pharmaceutical outsourcing market benefits from structural industry tailwinds with 10% long-term sales CAGR as evidence
Bear Case 8
  • PE ratio of 38.4x is elevated for a company delivering only 6% TTM sales growth, suggesting stretched valuations
  • TTM compounded profit growth has turned negative at -14%, indicating recent earnings deterioration
  • Return on equity of just 9.72% over last 3 years is low for a company trading at 2.98x book value
  • Recent sales growth has decelerated to 6% TTM from the 10% five-year CAGR, signaling a slowdown
  • Price-to-book ratio of 2.97x is high relative to the modest 8% ROE delivered in the last year
  • 5-year sales CAGR of 9.87% is considered poor growth for a mid-cap pharma company at premium valuations
  • ROE has declined from 10% (3-year average) to 8% in the last year, showing deteriorating capital efficiency
  • 5-year ROE average of only 6% suggests the company historically struggles to generate adequate returns on shareholder equity

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Positives 1
  • ₹3 dividend record date set Jun 16

    Akums fixed July 3, 2026 as record date for a final and special dividend of ₹3 per share, subject to shareholder approval at the AGM on July 10.

Neutral 2
  • BRSR FY26 ESG report filed Jun 18

    Akums filed its Business Responsibility and Sustainability Report for FY 2025-26 detailing energy consumption, waste management, and employee welfare metrics.

  • Investor meets in June Jun 10

    Akums scheduled investor meetings in Singapore and Mumbai on June 15, and hosted the InsightX 2026 Virtual Conference on June 12 at 12:00 noon IST. No unpublished price sensitive information shared.

TL;DR: Akums is maintaining steady shareholder engagement through investor conferences and a ₹3 per share dividend announcement. No material headwinds surfaced in the recent news cycle. The company's proactive ESG reporting and capital return signal stable governance. Near-term catalysts depend on AGM approval of the dividend on July 10 and any strategic updates from investor interactions.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
970
1,181
1,083
944
1,019
1,033
1,010
1,056
1,024
1,018
1,160
1,158
1,167
Expenses
1,095
1,029
989
941
891
912
889
962
895
923
1,013
1,006
992
Operating Profit
-125
152
93
3
128
121
121
94
129
94
147
152
175
OPM %
-13%
13%
9%
0.3%
13%
12%
12%
9%
13%
9%
13%
13%
15%
Other Income
8
-21
10
10
7
17
19
26
27
32
16
34
30
Interest
12
14
12
12
13
12
5
5
23
23
24
24
25
Depreciation
30
30
32
34
34
35
45
40
37
38
40
40
41
PBT
-159
87
59
-33
87
92
91
75
96
66
100
121
139
Tax %
18%
62%
-229%
20%
30%
27%
27%
-99%
32%
35%
32%
33%
27%
Net Profit
-187
33
195
-39
61
67
66
150
65
43
68
81
101
EPS in Rs
-13.16
2.22
13.54
-2.89
4.08
4.14
4.14
9.38
4.03
2.59
4.21
5.38
6.35
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,464
1,651
2,414
2,723
3,672
3,655
4,178
4,118
4,359
4,502
Expenses
1,340
1,507
2,240
2,485
3,761
3,361
4,055
3,654
3,837
3,934
Operating Profit
124
144
174
238
-89
294
123
465
522
568
OPM %
8%
9%
7%
9%
-2.4%
8%
3%
11%
12%
13%
Other Income
6
6
26
11
7
15
8
69
108
112
Interest
23
22
20
7
17
46
51
35
94
96
Depreciation
31
38
67
70
95
113
126
153
155
159
PBT
77
89
114
172
-193
150
-45
345
382
426
Tax %
51%
50%
62%
28%
30%
35%
-102%
0%
33%
—
Net Profit
43
61
44
123
-251
98
1
344
256
293
EPS in Rs
367
523
336
943
-35.3
6.63
-0.28
21.49
16.21
18.53
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
18%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
1
1
1
1
14
29
29
31
31
Reserves
493
628
721
884
608
689
681
3,016
3,283
Borrowings
255
213
175
130
395
619
565
88
157
Other Liabilities
293
318
1,140
1,137
2,033
1,905
2,229
960
1,958
Total Liabilities
1,042
1,161
2,037
2,152
3,050
3,241
3,504
4,095
5,429
Fixed Assets
444
501
645
904
1,021
1,097
1,191
1,397
1,456
CWIP
0
11
57
17
31
103
195
163
177
Investments
0
18
6
20
0
0
0
0
0
Other Assets
598
632
1,329
1,212
1,998
2,041
2,118
2,535
3,796
Total Assets
1,042
1,161
2,037
2,152
3,050
3,241
3,504
4,095
5,429
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
72
89
28
131
32
177
498
465
1,181
Investing
-150
-123
-190
-109
-235
-305
-331
-548
-930
Financing
66
37
233
-91
236
125
-108
73
34
Net Cash Flow
-11
4
71
-70
33
-4
59
-10
285
Free Cash Flow
-78
-34
-34
49
-224
-110
212
201
958
CFO/OP
72
98
44
74
-98
93
455
118
243
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
57
88
71
88
84
73
68
67
Inventory Days
114
115
99
93
112
117
90
102
110
Days Payable
67
60
105
74
92
91
76
96
87
Cash Conversion Cycle
115
112
82
90
109
111
87
74
89
Working Capital Days
78
73
55
66
49
46
40
71
66
ROCE %
—
14%
—
20%
-16%
22%
2%
16%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Akums Drugs & Pharma insights

68 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Shareholding Pattern

FIIs1.91%Promot.75.26%Others3.82%Public5.57%DIIs13.44%As ofJun 2026

Documents

Frequently Asked Questions about Akums Drugs & Pharma

What does Akums Drugs & Pharmaceuticals Ltd do?
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]
Where is Akums Drugs & Pharmaceuticals Ltd (AKUMS) listed?
Akums Drugs & Pharmaceuticals Ltd trades as AKUMS on the NSE and under code 544222 on the BSE.
Which sector does Akums Drugs & Pharmaceuticals Ltd belong to?
Akums Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹11,782 Cr, which places it in the Mid Cap band.
What is the PE ratio of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd trades at a PE ratio of 41.90, on earnings per share of ₹0, against a book value of ₹210.57 per share.
What is the 52-week high and low of Akums Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Akums Drugs & Pharmaceuticals Ltd has traded between ₹409.3 and ₹796.55.
Does Akums Drugs & Pharmaceuticals Ltd pay dividends?
Akums Drugs & Pharmaceuticals Ltd has a dividend yield of 0.40%.
What is the Return on Equity (ROE) of Akums Drugs & Pharmaceuticals Ltd?
Akums Drugs & Pharmaceuticals Ltd reported a return on equity of 7.70%. Its debt-to-equity ratio is 0.05.

Company Information

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Website akums.in
CEO Mr. Sanjeev Jain
Employees 7,536
Listed 2024-08-06
Face Value ₹ 2
Issued Size 15,73,93,988

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/AKUMS.md for Akums Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List